


PRODUCT INFORMATION



1-Stearoyl-2-Arachidonoyl-d₈-sn-glycero-3-PC

Item No. 10009431

CAS Registry No.: 161922-50-5
Formal Name: 1-ocatadeconyl-2R-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glyceryl-3-phosphorylcholine-5,6,8,9,11,12,14,15-d₈
Synonyms: 18:0/20:4-d₈-PC, PC(18:0/20:4-d₈), SAPC-d₈, 1-Stearoyl-2-Arachidonoyl-d₈-sn-glycero-3-Phosphatidylcholine, 1-Stearoyl-2-Arachidonoyl-d₈-sn-glycero-3-Phosphocholine
MF: C₄₆H₇₆D₈NO₈P
FW: 818.2
Chemical Purity: ≥95% (1-Stearoyl-2-Arachidonoyl-sn-glycero-3-PC)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₈); ≤1% d₀
Supplied as: A 500 µg/ml solution in ethanol
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

1-Stearoyl-2-arachidonoyl-d₈-sn-glycero-3-PC (SAPC-d₈) is intended for use as an internal standard for the quantification of SAPC (Item No. 10009864) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Description

SAPC is a phospholipid containing stearic acid (Item No. 10011298) and arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) at the sn-1 and sn-2 positions, respectively. It is a component of LDL and has been found in human stenotic aortic valves and atherosclerotic plaques.^{1,2} Levels of SAPC are increased in the subepithelial invasive region compared to the superficial region of tumor tissue samples from patients with superficial-type pharyngeal squamous cell carcinoma.³ SAPC unilamellar vesicles have been used as substrates to quantify the activity of secretory phospholipase A₂ (sPLA₂) in the presence or absence of inhibitors.⁴ SAPC has also been used in the formation of lipid bilayers to study the effects of lipid composition on bilayer phase transitions.⁵

References

1. Milne, G.L., Seal, J.R., Havrilla, C.M., et al. *J. Lipid Res.* **46**(2), 307-319 (2005).
2. Lehti, S., Käkälä, R., Hörkkö, S., et al. *PLoS One* **8**(6), e65810 (2013).
3. Ishikawa, S., Tateya, I., Hayasaka, T., et al. *Biomed. Res. Int.* **2017:5387913** (2017).
4. Schebb, N.H., Falck, D., Faber, H., et al. *J. Chromatogr. A* **1216**(27), 5249-5255 (2009).
5. Tada, K., Goto, M., Tamai, N., et al. *Ann. N.Y. Acad. Sci.* **1189**, 77-85 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM